Wednesday, April 13, 2022 Daily Archives

Rapid Process Development: How a Synthetic Depth Filter Offers a Platform Approach for Efficient Virus Filtration Operations

by

Virus filtration is a critical unit operation in recombinant protein purification processes. Process development of virus filtration operations typically strives to maximize filter capacity and improve process robustness. Adsorptive prefilters are often used to remove higher order protein aggregates and improve filter capacity. While adsorptive membrane prefilters offer easy scale up and implementation, their narrow operating window may result in extensive process development screening studies. By contrast, synthetic depth filters offer a wide operating window and the potential for a…

April 13, 2022

Drug Discovery: Screening Approaches for Rapid Assessment of Target Tractability

by

This webcast features: Nuska Tschammer, Head of DEL Lab Operations, WuXi AppTec. In recent years, increasing use of genetic, transcriptional and knock-out technologies led to numerous biologically validated targets, many of them in the category “first-in-classâ€. The core purpose of experimentally based tractability assessments is to evaluate if the target of interest can be modulated by a chemical entity. In the past, extensive HTS screening efforts were initiated to find starting points for the small molecule drug discovery. Today, direct…

April 13, 2022

Aurion Biotech secures $120m to advance cell therapy candidate

by

The funding will be used to develop Aurion Biotech’s first candidate, AURN001, a cell therapy aiming to treat corneal edema. Aurion Biotech is a clinical-stage biotech firm that is aiming to “restore vision to millions of patients†with its regenerative therapies. According to the firm, the raised funds will be used to file an IND to the US Food and Drug Administration (FDA) in order to begin clinical trials. Additionally, Aurion wants to submit an NDA to the Japan Pharmaceuticals…

April 13, 2022

VectorBuilder shells out $500m for China viral vector plant

by

VectorBuilder is constructing a $500 million gene delivery and research campus in Guangzhou, China to expand its capabilities and production capacity. Contract development manufacturing organization (CDMO) VectorBuilder, provides gene delivery solutions says it will take four years to build what it has named the “Gene Delivery Research and Manufacturing Campus.†According to the firm, the campus will include 30 production suites designed to manufacture lentivirus, plasmids, messenger RNA (mRNA), adeno-associated virus (AAV), cell lines and other types of viral and…

April 13, 2022